Q
Quan Chen
Researcher at Nankai University
Publications - 244
Citations - 20608
Quan Chen is an academic researcher from Nankai University. The author has contributed to research in topics: Medicine & Mitochondrion. The author has an hindex of 52, co-authored 154 publications receiving 16697 citations. Previous affiliations of Quan Chen include Chinese Academy of Fishery Sciences & Chinese Academy of Sciences.
Papers
More filters
Journal ArticleDOI
Identifying optimal candidates for postoperative adjuvant therapy among regional persistent/recurrent nasopharyngeal carcinoma patients after neck dissection
Sai-Lan Liu,Xiao-Yun Li,Xue Song Sun,Jingping Peng,Chao Lin,Jin Jie Yan,Quan Chen,Lin-Quan Tang,Shan-Shan Guo,Ling Guo,Li-Ting Liu,Hai Qiang Mai +11 more
TL;DR: In this paper , the clinical outcomes of patients with regional persistent/recurrent nasopharyngeal carcinoma (NPC) who received neck dissection, and evaluate the clinical benefit of postoperative adjuvant therapy (PAT) based on patients' positive lymph node counts (PLNs), extracapsular spread (ECS) and preoperative plasma EBV DNA levels.
Journal ArticleDOI
Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
Hai Qiang Mai,Quan Chen,Dongping Chen,Chaosu Hu,Kunyu Yang,Jiyu Wen,Jin-Gao Li,Yingrui Shi,Feng Jin,Ruilian Xu,Jianji Pan,Shenhong Qu,Ping Li,Chunhong Hu,Yi Chun Liu,Yi Jiang,Xiaohui He,Hung-Ming Wang,Darren Wan-Teck Lim,Rui-Hua Xu +19 more
TL;DR: Toripalimab in combination with Gemcitabine-Cisplatin (GP) chemotherapy showed significant improvement over chemotherapy alone in progression-free survival (PFS) as first-line treatment for recurrent or metastatic (r/m) NPC at the interim PFS analysis of JUPITER-02 (NCT03581786) study as discussed by the authors .
Journal ArticleDOI
[Retracted] Isoquercitrin inhibits the progression of pancreatic cancer in vivo and in vitro by regulating opioid receptors and the mitogen‑activated protein kinase signalling pathway
TL;DR: Huang et al. as discussed by the authors showed that the flow cytometric plots shown in Fig.2 had previously appeared in another article published in the journal Oncology reports, suggesting that data purportedly showing results obtained under different experimental conditions had been derived from the same original source.
Patent
Drug for adjusting activity of platelets, screening method, and applications thereof
TL;DR: In this paper, a drug for adjusting the activity of platelets, a reagent kit, a screening method therefor, and applications thereof in preventing or treating thrombotic thrombinocytopenic purpura (THC) and other diseases related survival period reduction of platelet.